What This Trial Looked At
Radiotherapy is one of the most established treatments for liver tumours, but it comes with a cost: the same radiation that targets cancerous tissue also produces a wave of oxidative stress in surrounding healthy cells, which contributes to the fatigue, nausea, loss of appetite and general decline in quality of life that patients consistently report during treatment. In 2011 a Korean research team led by Ki-Mun Kang published a randomised, placebo-controlled trial in Medical Gas Research testing a focused supportive-care question: can drinking hydrogen-rich water during radiotherapy protect quality of life without interfering with the treatment itself?
The trial recruited 49 patients receiving radiotherapy for malignant liver tumours and randomised them to drink either hydrogen-rich water (0.55–0.65 mM H2, produced via a metallic magnesium stick placed in drinking water) or visually identical placebo water for the 6-week treatment period. The researchers tracked global quality of life using the well-validated EORTC QLQ-C30 instrument, alongside blood markers of oxidative stress and the standard measure of tumour response.
What They Found
Patients who drank hydrogen-rich water during radiotherapy reported significantly better quality of life scores compared with the placebo group across the 6-week treatment course. The difference was meaningful on the QLQ-C30 — the standard quality-of-life scale used in oncology research — covering the symptom and functional domains that radiotherapy patients typically find most disruptive.
The biological side of the picture lined up with the patient-reported side. Reactive oxygen metabolites in the blood were lower in the hydrogen group, and blood oxidation potential was better maintained over the treatment period. These shifts are consistent with hydrogen’s known role as a selective antioxidant that crosses cell membranes and neutralises the most damaging radiation-induced reactive species.
Critically, tumour response to radiotherapy was no different between the hydrogen and placebo groups. The supportive-care benefit did not come at the cost of treatment effectiveness.
What This Means in Context
This trial sits in the supportive-care space — it is not a study of hydrogen as a cancer treatment, and the authors are explicit about that distinction. The intervention was designed to do what supportive care is meant to do: make the experience of treatment more bearable without changing the underlying medical plan.
What makes the result interesting is the specificity of the mechanism. Radiation-induced quality-of-life decline is driven in large part by oxidative damage to non-cancerous tissue, which is exactly the kind of damage hydrogen-rich water has been shown to reduce in laboratory work. The trial is moderate in size and was conducted at a single centre, so larger multicentre trials would help establish the effect more robustly. The authors concluded that hydrogen-rich water may be a potentially novel supportive strategy for managing the biological reaction to radiation-induced oxidative stress in cancer patients.
What It Means for You
If you or someone you love is going through radiotherapy, this trial is part of a small but growing body of evidence that hydrogen-rich water may help reduce the quality-of-life toll of treatment without interfering with the treatment itself. Hydrogen-rich water is not a cancer treatment, and it is not a substitute for the care your oncology team is providing. Any complementary approach during active cancer treatment should be discussed with your treating oncologist first.
Citation: Kang, K.-M., Kang, Y.-N., Choi, I.-B., Gu, Y., Kawamura, T., Toyoda, Y., & Nakao, A. (2011). Effects of drinking hydrogen-rich water on the quality of life of patients treated with radiotherapy for liver tumors. Medical Gas Research, 1, 11. PubMed
